NDA 213135 · Azurity
Sutab
Magnesium Sulfate, Potassium Chloride, Sodium Sulfate · Oral
OrphanLast checked: Nov 20, 2026Latest source record: Oct 24, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Nov 10, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 1 recruiting
FAERS reports
1,589
211 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2026.
SUTAB is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. SUTAB is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SUTAB · MAGNESIUM SULFATE 0.225GM; POTASSIUM CHLORIDE 0.188GM; SODIUM SULFATE 1.479GM · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sutab" as an intervention, any sponsor and status, largest first.
- Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) TrialPivotal-lookingRecruiting
Morehouse School of MedicineAcademic, hospital or other
NCT07215000 · 300 participants (planned) · Start Oct 1, 2025 · Primary completion Jan 2027
Drug: Golytely; Sulfave and 1 more · For: Colorectal Cancer Screening; Bowel Cleansing for Colonoscopy
Sites: Atlanta, Georgia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting827
- nausea424
- drug ineffective141
- abdominal distension94
- headache94
- abdominal pain upper88
- pruritus66
- wrong technique in product usage process65
- abdominal pain63
- dizziness62
- tremor61
- chills56
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 263 |
| 2022 | 438 |
| 2023 | 426 |
| 2024 | 46 |
| 2025 | 397 |
| 2026 | 16 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sutab (Sod Sulf/Pot Chloride/Mag Sulf)
2024 spending
$25.4M
Beneficiaries
152,205
156,816 claims
Per beneficiary
$167
$6.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $9,897,287 |
| 2022 | $20,354,859 |
| 2023 | $29,113,137 |
| 2024 | $25,360,554 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.